Skip to main content

Table 5 Top 10 cited documents of biosimilars research. Scopus 2004–2016

From: A bibliometric analysis of the global research on biosimilars

Rank Title Year Journal name Cited by Type of document
1 EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2013 update 2014 Annals of the Rheumatic Diseases 962 Article
2 2010 update of EORTC guidelines for the use of granulocyte-colony stimulating factor to reduce the incidence of chemotherapy-induced febrile neutropenia in adult patients with lymphoproliferative disorders and solid tumours 2011 European Journal of Cancer 498 Article
3 Biopharmaceutical benchmarks 2014 2014 Nature Biotechnology 275 Article
4 A randomised, double-blind, parallel-group study to demonstrate equivalence in efficacy and safety of CT-P13 compared with innovator infliximab when coadministered with methotrexate in patients with active rheumatoid arthritis: The PLANETRA study 2013 Annals of the Rheumatic Diseases 269 Article
5 A randomised, double-blind, multicentre, parallel-group, prospective study comparing the pharmacokinetics, safety, and efficacy of CT-P13 and innovator infliximab in patients with ankylosing spondylitis: The PLANETAS study 2013 Annals of the Rheumatic Diseases 250 Article
6 Analytical tools for characterizing biopharmaceuticals and the implications for biosimilars 2012 Nature Reviews Drug Discovery 215 Review
7 PEG-modified biopharmaceuticals 2009 Expert Opinion on Drug Delivery 201 Review
8 The challenge of biosimilars 2008 Annals of Oncology 178 Review
9 Sublingual immunotherapy: World Allergy Organization position paper 2013 update 2014 World Allergy Organization Journal 172 Review
10 Biosimilars: What clinicians should know 2012 Blood 158 Review